ACCESSWIRE
06 Aug 2022, 03:25 GMT+10
NEW YORK, NY / ACCESSWIRE / August 5, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
CONTACT JAKUBOWITZ ABOUT VRCA:
https://claimyourloss.com/securities/verrica-pharmaceuticals-inc-loss-submission-form/?id=30626&from=1
Class Period : May 28, 2021 - May 24, 2022
Lead Plaintiff Deadline : August 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Outset Medical, Inc. (NASDAQ:OM)
CONTACT JAKUBOWITZ ABOUT OM:
https://claimyourloss.com/securities/outset-medical-loss-submission-form/?id=30626&from=1
This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.
Lead Plaintiff Deadline : September 6, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.
Enochian BioSciences, Inc. (NASDAQ:ENOB)
CONTACT JAKUBOWITZ ABOUT ENOB:
https://claimyourloss.com/securities/enochian-biosciences-inc-loss-submission-form/?id=30626&from=1
Class Period : January 17, 2018 - June 27, 2022
Lead Plaintiff Deadline : September 26, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
Get a daily dose of Tennessee Daily news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Tennessee Daily.
More InformationWARSAW, Poland: Julie, who preferred not to give her full name, booked a group of trips to Warsaw last year, ...
SYDNEY, NSW, Australia - Stocks traded lower in Asia on Wednesday. Technology stocks were the hardest hit, and the exchange ...
WASHINGTON D.C.: As prices for food and other basic staples are rising, U.S. demand for grocery deliveries is cooling, with ...
KUALA LUMPUR, Malaysia - After almost four years, the Bangladesh High Commission in Malaysia on Tuesday welcomed the first group ...
NEW YORK, New York - U.S. stocks fell Tuesday, with broad-based losses across the board. The technology sector, however, wore ...
ISTANBUL, Turkey: Turkey's current accounts are expected to record a deficit of $3.4 billion in June and end the year ...
LOS ANGELES, California: During a meeting that was disrupted by protesters this week, the Los Angeles City Council voted to ...
WASHINGTON D.C.: The U.S. Justice Department announced this week that former Puerto Rico governor Wanda Vazquez has been arrested in ...
NEW YORK CITY, New York: Amazon announced this week that it had purchased robotic vacuum maker iRobot for approximately $1.7 ...
RICHMOND, Virginia: Dominion Energy Virginia has received state approval to build an enormous offshore wind farm off the coast of ...
DEATH VALLEY NATIONAL PARK, California: Record rainfall on August 5 caused floods at Death Valley National Park that closed all ...
KATHMANDU, Nepal - Nepal says it is closely monitoring the recent Taiwan issue and remains committed to the one-China policy.Sewa ...